Moreover, the treatment of liver macrophages with synthetic RORα ligands was found to modulate nonalcoholic steatohepatitis (NASH); activation of RORα by SR1078 [52] as an RORα agonist results in protection against NASH and loss of RORα function, whereas inhibition of RORα function by SR3335 [25], an RORα-selective inverse agonist, results in the progression of NASH [53]. This evidence concerns the gene RORA and metabolic dysfunction-associated steatohepatitis.